Speedy EU review for Shire’s lanadelumab
admin 28th February 2018 Uncategorised 0European regulators will undertake an accelerated assessment of Shire’s hereditary angioedema (HAE) drug lanadelumab. More: Speedy EU review for Shire’s lanadelumab Source: News
read more